• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Juvaris BioTherapeutics

edit

Juvaris BioTherapeutics, Inc. is developing adjuvanted vaccines and immunotherapeutics to treat infectious disease and cancer.

The Company’s platform technology induces profound immunostimulation via cationic lipid-DNA (non-coding) complexes (CLDC). The Company’s lead product candidate, JVRS-100, stimulates adaptive and innate immune responses at levels many fold higher than other drugs in its class. JVRS-100 is in clinical development as a vaccine adjuvant and an immunotherapeutic.

Recent Milestones

edit

• 
  Juvaris BioTherapeutics received $12.5M in Series B funding. (4/12/10)
  Posted 4/12/10 at 6:52pm via onbiovc.com
• 
  Juvaris BioTherapeutics received $25M in Series B funding. (1/27/10)
  Posted 1/27/10 at 9:57pm via finsmes.com
• 
  Juvaris BioTherapeutics received $9M in Grant funding. (8/2/07)
  Posted 9/9/09 at 8:11am via venturebeat.com
• 
  Juvaris BioTherapeutics received $7.53M in Series A funding. (1/5/07)
  Posted 7/23/09 at 7:46pm via venturebeat.com

Videos

Screenshots

edit

Above: Juvaris BioTherapeutics
Uploaded: 7/24/09

Sources

1. Cancer vaccine developer Juvaris raises $7.53M, led by Kleiner Perkins (deals.venturebeat.com) [edit]
2. Vaccine maker Juvaris Bio gets $9M government grant (deals.venturebeat.com) [edit]
3. Juvaris BioTherapeutics Completes Second Close on $25M Series B Financing (finsmes.com) [edit]
4. Juvaris BioTherapeutics, Inc.: Series B $12.5M (onbiovc.com) [edit]